Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis

Experimental Dermatology

Volumn 15, Issue 5, 2006, Pages 368-376

  Barile, S ^a   Medda, E ^b   Nistico L ^b   Bordignon, V ^a   Cordiali Fei, P ^a   Carducci, M ^a   Rainaldi, A ^c   Marinelli, R ^c   Bonifati, C ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

Angiogenesis; Onset; Psoriasis; SNPs; VEGF

Indexed keywords

ADENINE; CYTOSINE; GUANINE; THYMINE; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENDER; GENE LOCUS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROTEIN BLOOD LEVEL; PSORIASIS; RISK ASSESSMENT; SKIN DISEASE; STATISTICAL SIGNIFICANCE; 5' UNTRANSLATED REGION; AGED; BLOOD; CASE CONTROL STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; ITALY; MIDDLE AGED; PROMOTER REGION;

5' UNTRANSLATED REGIONS; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ITALY; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PSORIASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745263074     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2006.00416.x     Document Type: Article

References (50)

1. Schon M P, Boechncke W H. Psoriasis. N Engl J Med 2005: 352: 1899-1912.
2. Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 2002: 5: 231-236.
3. Braverman I M, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 1982: 78 (5): 17.
4. Telner P, Fekete Z. The capillary responses in psoriatic skin. J Invest Dermatol 1961: 36 (225): 30.
5. De Boer O J, Verhagen C E, Visser A, Bos J D, Das P K. Cellular interactions and adhesion molecules in psoriatic skin. Acta Derm Venereol Suppl (Stockh) 1994: 186: 15-18.
6. Nickoloff B J. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: Human skin model of psoriasis. J Investig Dermatol Symp Proc 2000: 5: 67-73.
7. Deng H, Yan C L, Hu Y, Xu Y, Liao K H. Photochemotherapy inhibits angiogenesis and induces apoptosis of endothelial cells in vitro. Photodermatol Photoimmunol Photomed 2004: 20: 191-199.
8. Detmar M, Brown L F, Claffey K P. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994: 180: 1141-1146.
9. Detmar M. Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol 2004: 122: 209-215.
10. Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. J Biol Chem 1991: 266: 11947-11954.
11. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: A historical review. Br J Haematol 2005: 128: 303-309.
12. Zhang Y, Matsuo H, Morita E. Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales. Exp Dermatol 2005: 14: 758-764.
13. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997: 18: 4-25.
14. Melter M, Reindus M E, Sho M et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000: 96: 3801-3808.
15. Freeman M R, Schneck F X, Gagnon M L et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 1995: 55: 4140-4145.
16. Reinders M E J, Sho M, Izawa A. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003: 112: 1655-1665.
17. Gille J, Swerlick R A, Caughman W. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997: 16: 750-759.
18. Kwon Y W, Kwon K S, Moon H E et al. Insulin-like growrth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HACAT. J Invest Dermatol 2004: 123: 152-158.
19. Malaguarnera L, Imbesi R, Di Rosa M. Action of prolactin, IFN-gamma, TNF-alpha and LPS on heme oxygenase-1 expression and VEGF release in human monocytes/macrophages. Int Immunopharmacol 2005: 5: 1458-1469.
20. Valter M M, Wiestler O D, Pietsche T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. Int J Dev Neurosci 1999: 17: 565-577.
21. Cohen T, Nahari D, Cerem L W, Neufeld G, Levi B Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996: 271: 736-741.
22. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999: 38: 241-251.
23. Xia Y P, Li B, Hylton D, Detmar M, Yancopoulos G D, Rudge J S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003: 102: 161-168.
24. Diaz B V, Lenoir M C, Ladoux A, Frelin C, Demarchez M, Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000: 275: 642-650.
25. Hernandez G L, Volpert O V, Iniguez M A et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001: 193: 607-620.
26. Sauder D N, Dekoven J, Champagne P, Croteau D, Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002: 47: 535-541.
27. Brogan I J, Khan N, Isaac K, Hutchinson J A, Pravica V, Hutchinson I V. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999: 60: 1245-1249.
28. Watson C J, Webb N J A, Bottomley M J, Brenchley P E C. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in vegf protein production. Cytokine 2000: 8: 1232-1235.
29. Awata T, Inona K, Kurihara S et al. A common polymorphism in the 5′-untraslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002: 51: 1635-1639.
30. Shahbazi M, Fryer A A, Pravica V et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002: 13: 260-264.
31. Lambrechts D, Storkebam E, Morimoto M et al. Vegf is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003: 34: 383-394.
32. Yang B, Cross D F, Ollerenshaw M, Millward B A, Demaine A G. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 2003: 17: 1-6.
33. Awata T, Kurihara S, Takata N et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005: 333: 679-685.
34. Del Bo R, Scarlato M, Ghezzi S et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 2005: 57: 373-380.
35. Koukourakis M I, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004: 46: 293-298.
36. Salvarani C, Boiardi L, Casali B et al. Vascular endothelial growth factor gene polymorphisms in Behcet's disease. J Rheumatol 2004: 31: 1785-1789.
37. Boiardi L, Casali B, Nicoli D et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. Rheumatol 2003: 30: 2160-2164.
38. Young H S, Summers A M, Bhushan M, Brenchley P E, Griffiths C E. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004: 122: 209-215.
39. Fredriksson T, Pettersson U. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica 1978: 157: 238-244.
40. Stevens A, Soden J, Brenchley P E, Ralph S, Ray D W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003: 63: 812-816.
41. Craven N M, Jackson C W, Kirby B et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001: 144: 849-853.
42. Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun 2003: 4: 455-457.
43. Tsunemi Y, Nishibu A, Saeki H et al. Lack of association between the promoter polymorphisms at positions -308 and -238 of the tumor necrosis factor alpha gene and psoriasis vulgaris in Japanese patients. Dermatology 2003: 207: 371-374.
44. Mossner R, Kingo K, Kleensang A et al. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 2005: 124: 282-284.
45. Ioannidis J P, Ntzani E E, Trikalinos T A, Contopoulos-Ioannidis D G. Replication validity of genetic association studies. Nat Genet 2001: 29: 306-309.
46. Mohammadi M, Ollier W E R, Hutchinson I V et al. A functional association study of gene promoter polymorphisms with vegf expression by stimulated pbm cells. Hum Immunol 2003: 64: S125.
47. Bushan M, McLaughlin B, Weiss J B, Griffith C E M. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999: 141: 1054-1060.
48. Nielsen H J, Christensen I J, Svendsen M N et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002: 51: 563-567.
49. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002: 138: 791-796.
50. Reich K, Mossner R, Konig I R, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002: 118: 155-163.